GlucoTrack Inc.
GCTK | NASDAQ
$2.27
-$0.03 (-1.30%)
Sep 22, 2026, 11:49 AM ET · Market open
Company Profile
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | CEO & Director |
| Avner Gal MSc.EE | Co-Founder, Chairman Emeritus & Consultant |
| David Malka | Co-Founder |
| Drinda Benjamin | Chief Commercial Officer |
| Mark Tapsak | Chief Scientific Officer |
| Paul V. Goode | Chief Technical Officer, President & Director |
| Vincent Wong | Chief Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 425 | Filing |
| Aug 28, 2026 | 8-K/A | [Amend] Current Report |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 21, 2026 | DEFA14A | Filing |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | DEF 14A | Filing |
| Aug 10, 2026 | 8-K | Current Report |
GlucoTrack Inc.
| Country | United States |
| IPO Date | Apr 24, 2013 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Erik Emerson |
Contact Details
301 Route 17 North Rutherford,
New Jersey 07070 United States
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506983 |
| CUSIP Number | 45824Q887 |
| ISIN Number | US45824Q8877 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove GCTK